Is Elutia Inc (ELUT) a Buy, Sell, or Hold?
NASDAQ : ELUT
Elutia Inc
$0.95 USD
$0.02 (2.14%)
- Volume
- 49.77K
- Average Volume
- 116.23K
- Market Capitalization
- $42M
- P/E Ratio
- 0.76
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $2.50
- Year Low
- $0.50
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.05
Company Overview
NASDAQ
C. Randal Mills
Biotechnology
Healthcare
ELUT
26
US
USD
Liquidity Metrics
0.19
2.05
1.94
1.20
0.00
Sales & Valuation
$12.29M
2.63
1.81
-0.92
-1.07
Profitability
-$0.79
$53.38M
312.09%
-152.29%
-560.64%
90.28%
P/E Metrics
0.76
0.00
0.00
Analyst Price Target & Rating
$10.00
$10.50
$5.00
4/5
5 Analysts
-90.50%
Financial Health Scores
-4.69
5/9
$24.87M
$55.21M
$32.68M
-$27.28M
Key Metrics (TTM)
$17.68M
1.11
-0.71
2.05
-560.64%
-78.27%
122.15%
-109.21%
$3.70
-13 days
Company Executives
| Name | Title |
|---|---|
| C. Randal Mills | Co-Founder, President, Chief Executive Officer & Director |
| Michelle LeRoux Williams | Chief Scientific Officer |
| Sonali Fonseca | Vice President & Head of Emerging Businesses |
| Tamara Grossett | Head of People |
| Dwayne Montgomery | Head of Cardiovascular |
| Jeffry D. Hamet | Senior Vice President of Finance, Treasurer & Secretary |
| Matthew Ferguson | Chief Financial Officer |
| Pete J. Ligotti | Chief Commercial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Elutia Inc (NASDAQ:ELUT) Stock
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable ... matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
2026-07-16 16:05:00
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
Elutia to Present at Planet MicroCap Showcase 2026 on June 17th
2026-06-11 16:05:00
GAITHERSBURG, Md., June 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Dr. Michelle Williams, Chief Scientific Officer, will present and host one-on-one meetings with investors at the Planet MicroCap Showcase 2026 at the Bellagio in Las Vegas, Nevada on June 17–18, 2026.
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2026-05-18 16:05:00
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on May 13, 2026 to one new employee as an inducement award under the Elutia Inc. 2026 Inducement Award Plan (the “Plan”).
Elutia Inc. (ELUT) Q1 2026 Earnings Call Transcript
2026-05-14 20:10:46
Elutia Inc. (ELUT) Q1 2026 Earnings Call Transcript
2026-05-14 16:05:00
NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparations Brought a new automated manufacturing process online, supporting a gross margin target of more than 80% at scale Chief Commercial Officer Pete Ligotti's initial surgeon engagement confirming significant unmet need and market opportunity Strong balance sheet with $36.5 million in cash and escrowed proceeds from the BioEnvelope business divestiture Conference call today at 5:00 p.m. ET / 2:00 p.m.
Elutia to Present at the 16th Annual LD Micro Invitational on May 18th
2026-05-14 16:01:00
GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the 16th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California on May 18, 2026.
Elutia to Present at the 16th Annual LD Micro Invitational May 18th
2026-05-14 16:01:00
Gaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Elutia Inc. (NASDAQ: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present and host one-on-one meetings with investors at the 16th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California on May 18, 2026. During the presentation, management will discuss how Elutia is working to address post-surgical infection in implant-based breast reconstruction following mastectomy-one of the most significant challenges facing patients and surgeons-through its drug-eluting biomatrix technology designed to support safer, more reliable reconstructive outcomes.
Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
2026-04-30 16:05:00
GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2026 financial results after market close on Thursday, May 14, 2026.
Frequently Asked Questions
-
What is the current Elutia Inc (ELUT) stock price?
-
Elutia Inc(NASDAQ:ELUT) stock price is $0.95 in the last trading session. During the trading session, ELUT stock reached the peak price of $2.5 while $0.5 was the lowest point it dropped to. The percentage change in ELUT stock occurred in the recent session was 2.14% while the dollar amount for the price change in ELUT stock was $0.02.
-
ELUT's industry and sector of operation?
-
The NASDAQ listed ELUT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ELUT?
-
C. Randal Mills | Co-Founder, President, Chief Executive Officer & Director
Michelle LeRoux Williams | Chief Scientific Officer
Sonali Fonseca | Vice President & Head of Emerging Businesses
Tamara Grossett | Head of People
Dwayne Montgomery | Head of Cardiovascular -
How many employees does ELUT have?
-
Number of ELUT employees currently stands at 26. ELUT operates from 20 Firstfield Road, Gaithersburg, MD 20878, US.
-
Link for ELUT official website?
-
Official Website of ELUT is: https://elutia.com
-
How do I contact ELUT?
-
ELUT could be contacted at phone #240 247 1170 and can also be accessed through its website. ELUT operates from 20 Firstfield Road, Gaithersburg, MD 20878, US.
-
How many shares of ELUT are traded daily?
-
The average number of ELUT shares traded daily for last 3 months was 116.23K.
-
What is the market cap of ELUT currently?
-
The market value of ELUT currently stands at $42M with its latest stock price at $0.95